CardioNet Launches Enhanced Reporting Package for the Treatment of Atrial Fibrillation
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, today announced the release of its new atrial fibrillation (AF) reporting package to enhance its current AF Management Program.
The CardioNet AF Management Program offers a robust and comprehensive tool to the physician for the diagnosis, treatment and management of their AF patients. The program additionally provides physicians with an efficient and flexible monitoring program to evaluate the clinical efficacy of catheter and surgical ablation procedures allowing improved management of these post surgical patients. CardioNet President and CEO, Arie Cohen, said of the new reporting package, “Our goal to continually provide physicians and patients with state of the art capabilities is evident in today’s announcement, and we expect that our products and services will continue to improve patient lives and drive physician adoption of the CardioNet System.”
The reporting enhancements will strengthen CardioNet’s current proprietary correlated Heart Rate Trend Chart and AF Burden Graph by providing detailed atrial fibrillation statistics, including the duration of AF episodes, the percentage of time that a patient is in AF over a twenty four hour period, and heart rate trends while the patient is in AF. Dr. Peter R. Kowey, CardioNet Medical Director and Chief, Division of Cardiovascular Diseases at the Main Line Health System, said, “Quantifying the amount of AF over time represents a very important advance in caring for patients with this common arrhythmia.” The CardioNet System is widely utilized by physicians and is proven to be nearly three times superior at detecting clinically significant atrial fibrillation(1), a condition which affects 2.2 million people in the United States.
CardioNet is the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual’s health. CardioNet’s initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as the CardioNet System. More information can be found at http://www.cardionet.com.
(1) Journal of Cardiovascular Electrophysiology (Vol. 18, No. 2, March 2007).
Forward Looking Statements
This press release includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our ability to continue to increase physician adoption and the positive impact of our AF reporting on that process. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, the success of our sales and marketing initiatives, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development and marketing, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection and litigation. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our Annual Report and Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.